---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Care management intervention strategies"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Care management intervention strategies. Topics: Nursing considerations before and during instillation, Patient education and follow-up after instillation, Response surveillance schedule in BOND-003, Re-induction for persistent disease at 3 months, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Nursing considerations before and during instillation

> “Review patient history (difficult catheterizations, UTI, etc)”
> “Ensure bladder is emptied prior to instillation”
> “Administered with foley (indwelling with balloon)”
> “Administration allows patient throughput and comfort”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.2.2.4-2"></a>

### Patient education and follow-up after instillation

> “Provide instructions and resources for post treatment care”
> “Close contact with loved ones is acceptable if patient is free from cold- or flu-like symptoms”
> “Counsel on the importance of open communication with the care team regarding potential side effects”
> “Reinforce importance of ongoing NMIBC surveillance and adherence to the treatment plan”
> “Nurses and APPs play a vital role integrating novel bladder cancer therapies and enhancing patient experience”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

<a id="topic-2.2.2.4-3"></a>

### Response surveillance schedule in BOND-003

> “Response assessments: cystoscopy (± biopsy) & cytology q3mo × 2yrs, then q6mo starting Yr 3; all responses centrally confirmed”

Source: [Donahue et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SUNA_Cretostimogene-Nursing-Logisitics_Final-1.pdf)

> “All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-2.2.2.4-4"></a>

### Re-induction for persistent disease at 3 months

> “Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-2.2.2.4-5"></a>

### Treatment adherence and resolution of treatment-related adverse events

> “Most AES were Grade 1-2; 1-day median time to TRAE resolution”
> “High Tx Compliance- no tx-related discontinuations; few missed (1.8%) or delayed (7.1%) doses”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-2.2.2.4-6"></a>

### Cystectomy decisions with comparator bladder-sparing therapies

> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

> “Delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal.”

Source: [Anktiva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761336s002lbl.pdf)

<a id="topic-2.2.2.4-7"></a>

### Multidisciplinary tumour board review

> “Discuss high-risk and very high-risk patients within a multidisciplinary board, when possible.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
